PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
July 24, 2023The Journal of Maternal-Fetal & Neonatal Medicine9 citationsOpen Access

Oral nifedipine versus intravenous labetalol for hypertensive emergencies during pregnancy: a systematic review and meta-analysis

View Full Paper
LLLin LiWXWenxia XieHXHao Xu

Structured PICO

Does oral nifedipine reduce the time to reach target blood pressure compared to intravenous labetalol in pregnant women with hypertensive emergencies?

P
Population
1151 pregnant women with hypertensive emergencies (pooled from 12 RCTs)
I
Intervention
Oral nifedipine
C
Comparator
Intravenous labetalol
O
Outcome
Time to reach target blood pressuresurrogate

Oral nifedipine achieves target blood pressure more rapidly and requires fewer doses than intravenous labetalol in the management of hypertensive emergencies during pregnancy, with a similar safety profile.

Abstract

Aim: The optimal drug management strategy for severe hypertension during pregnancy remains inconclusive. Some randomized controlled trials found that oral nifedipine was more effective than intravenous labetalol in hypertensive emergencies during pregnancy, while others found otherwise. As a result, we conducted a meta-analysis to assess the effectiveness of oral nifedipine versus intravenous labetalol for hypertensive emergencies during pregnancy.Methods: We searched PubMed, Embase, and the Cochrane Library for randomized controlled trials that compared oral nifedipine versus IV labetalol in hypertensive emergencies during pregnancy.Results: 12 RCTs enrolling 1151 participants (573 in the labetalol group and 578 in the nifedipine group) were included in the meta-analysis. Patients who received oral nifedipine reached their target blood pressure more rapidly than those who received intravenous labetalol (MD 7.64, 95%CI 4.08–11.20, p < .0001). The nifedipine group required fewer doses to achieve the target blood pressure (MD 0.62, 95%CI 0.36 to 0.88, p < .00001). There were no meaningful differences on the maternal complications between the two groups, mainly including eclampsia (OR 1.51; 95% CI, 0.75–3.05; p = .25), headache (OR 0.86; 95% CI, 0.52–1.44; p = .57), nausea/vomiting (OR 1.50; 95% CI, 0.76–2.93; p = .24), hypotension (OR 0.49; 95% CI, 0.12–1.99; p = .32), dizziness (OR 2.01; 95% CI, 0.77–5.25; p = .16), HELLP (OR 0.27; 95% CI, 0.05–1.64; p = .16), palpitations (OR 0.63; 95% CI, 0.32–1.27; p = .20), flushing (OR 0.77; 95%CI, 0.18–3.22; p = .72). There were no significant difference in the neonatal complications, including NICU admission (OR 1.24; 95% CI, 0.87–1.77; p = .23), 5 min Apgar score < 7 (OR 1.07; 95% CI, 0.82–1.39; p = .63), neonatal deaths (OR 1.08; 95%CI, 0.66–1.76; p = .77), FHR abnormality (OR 0.94; 95%CI, 0.47–1.88; p = .86).Conclusion: In conclusion, oral nifedipine could achieve target blood pressure more rapidly and required fewer doses than intravenous labetalol in the management of hypertensive emergencies during pregnancy.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Li et al. (2023) studied this question.

synapsesocial.com/papers/6a894ca04e16d35695eb1a02https://doi.org/10.1080/14767058.2023.2235057
Ask AI
Helpful
Bookmark
Share
View Full Paper